<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01754766</url>
  </required_header>
  <id_info>
    <org_study_id>229666-002</org_study_id>
    <nct_id>NCT01754766</nct_id>
  </id_info>
  <brief_title>AGN-229666 for the Treatment of Allergic Conjunctivitis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of AGN-229666 for the treatment of allergic
      conjunctivitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular Itching Score at Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>The participant evaluated ocular itching in both eyes 5 minutes post conjunctival allergen challenge (CAC) (8 hours post-dose) at Day 1 using a 9-point scale in half-unit increments where: 0=none to 4=incapacitating itch with an irresistible urge to rub. The score for each participant was the average of the score of both eyes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ocular Itching Score at Day 15</measure>
    <time_frame>Day 15</time_frame>
    <description>The participant evaluated ocular itching in both eyes 5 minutes post conjunctival allergen challenge (16 hours post-dose) at Day 15 using a 9-point scale in half-unit increments where: 0=none to 4=incapacitating itch with an irresistible urge to rub. The score for each participant was the average of the score of both eyes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conjunctival Hyperemia Score</measure>
    <time_frame>Day 1</time_frame>
    <description>Conjunctival hyperemia is the engorgement of the blood vessels (redness) of the clear membrane covering the white surface of the eye. Conjunctival hyperemia was evaluated 15 minutes post conjunctival allergen challenge (CAC) (8 hours post dose) on Day 1 for both eyes using a 9-point scale in half-unit increments where: 0=none to 4=Extremely severe. The score for each participant was the average of the score of both eyes.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Allergic Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>AGN-229666 Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop of AGN-229666 Dose A into each eye on Day 1 and Day 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AGN-229666 Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop of AGN-229666 Dose B into each eye on Day 1 and Day 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vehicle of AGN-229666</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One drop of vehicle of AGN-229666 into each eye on Day 1 and Day 15.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN-229666</intervention_name>
    <description>One drop of AGN-229666 into each eye on Day 1 and Day 15.</description>
    <arm_group_label>AGN-229666 Dose A</arm_group_label>
    <arm_group_label>AGN-229666 Dose B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>vehicle of AGN-229666</intervention_name>
    <description>One drop of vehicle of AGN-229666 into each eye on Day 1 and Day 15.</description>
    <arm_group_label>vehicle of AGN-229666</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese patients living in Japan with a history of allergic conjunctivitis

          -  Willing to discontinue wearing contact lenses during the study period

        Exclusion Criteria:

          -  Use of nicotine products during the study period

          -  Presence of active eye infection (bacterial, viral, or fungal)

          -  History of an ocular herpetic infection

          -  Eye surgery intervention within 3 months and/or a history of refractive surgery within
             the past 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2012</study_first_submitted>
  <study_first_submitted_qc>December 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2012</study_first_posted>
  <results_first_submitted>December 17, 2013</results_first_submitted>
  <results_first_submitted_qc>December 17, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 4, 2014</results_first_posted>
  <last_update_submitted>December 17, 2013</last_update_submitted>
  <last_update_submitted_qc>December 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AGN-229666 Dose A</title>
          <description>One drop of AGN-229666 Dose A into each eye on Day 1 and Day 15.</description>
        </group>
        <group group_id="P2">
          <title>AGN-229666 Dose B</title>
          <description>One drop of AGN-229666 Dose B into each eye on Day 1 and Day 15.</description>
        </group>
        <group group_id="P3">
          <title>Vehicle of AGN-229666</title>
          <description>One drop of vehicle of AGN-229666 into each eye on Day 1 and Day 15.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Personal reasons</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AGN-229666 Dose A</title>
          <description>One drop of AGN-229666 Dose A into each eye on Day 1 and Day 15.</description>
        </group>
        <group group_id="B2">
          <title>AGN-229666 Dose B</title>
          <description>One drop of AGN-229666 Dose B into each eye on Day 1 and Day 15.</description>
        </group>
        <group group_id="B3">
          <title>Vehicle of AGN-229666</title>
          <description>One drop of vehicle of AGN-229666 into each eye on Day 1 and Day 15.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="30"/>
            <count group_id="B4" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>20-30 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;30-40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ocular Itching Score at Day 1</title>
        <description>The participant evaluated ocular itching in both eyes 5 minutes post conjunctival allergen challenge (CAC) (8 hours post-dose) at Day 1 using a 9-point scale in half-unit increments where: 0=none to 4=incapacitating itch with an irresistible urge to rub. The score for each participant was the average of the score of both eyes.</description>
        <time_frame>Day 1</time_frame>
        <population>Modified Intent-to-treat (MITT) population included all randomized participants with ocular itching score data available for this time point</population>
        <group_list>
          <group group_id="O1">
            <title>AGN-229666 Dose A</title>
            <description>One drop of AGN-229666 Dose A into each eye on Day 1 and Day 15.</description>
          </group>
          <group group_id="O2">
            <title>AGN-229666 Dose B</title>
            <description>One drop of AGN-229666 Dose B into each eye on Day 1 and Day 15.</description>
          </group>
          <group group_id="O3">
            <title>Vehicle of AGN-229666</title>
            <description>One drop of vehicle of AGN-229666 into each eye on Day 1 and Day 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Itching Score at Day 1</title>
          <description>The participant evaluated ocular itching in both eyes 5 minutes post conjunctival allergen challenge (CAC) (8 hours post-dose) at Day 1 using a 9-point scale in half-unit increments where: 0=none to 4=incapacitating itch with an irresistible urge to rub. The score for each participant was the average of the score of both eyes.</description>
          <population>Modified Intent-to-treat (MITT) population included all randomized participants with ocular itching score data available for this time point</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.500" spread="0.5123"/>
                    <measurement group_id="O2" value="0.319" spread="0.3947"/>
                    <measurement group_id="O3" value="1.867" spread="0.9485"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Itching Score at Day 15</title>
        <description>The participant evaluated ocular itching in both eyes 5 minutes post conjunctival allergen challenge (16 hours post-dose) at Day 15 using a 9-point scale in half-unit increments where: 0=none to 4=incapacitating itch with an irresistible urge to rub. The score for each participant was the average of the score of both eyes.</description>
        <time_frame>Day 15</time_frame>
        <population>Modified Intent-to-treat (MITT) population included all randomized participants with ocular itching score data available for this time point</population>
        <group_list>
          <group group_id="O1">
            <title>AGN-229666 Dose A</title>
            <description>One drop of AGN-229666 Dose A into each eye on Day 1 and Day 15.</description>
          </group>
          <group group_id="O2">
            <title>AGN-229666 Dose B</title>
            <description>One drop of AGN-229666 Dose B into each eye on Day 1 and Day 15.</description>
          </group>
          <group group_id="O3">
            <title>Vehicle of AGN-229666</title>
            <description>One drop of vehicle of AGN-229666 into each eye on Day 1 and Day 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Itching Score at Day 15</title>
          <description>The participant evaluated ocular itching in both eyes 5 minutes post conjunctival allergen challenge (16 hours post-dose) at Day 15 using a 9-point scale in half-unit increments where: 0=none to 4=incapacitating itch with an irresistible urge to rub. The score for each participant was the average of the score of both eyes.</description>
          <population>Modified Intent-to-treat (MITT) population included all randomized participants with ocular itching score data available for this time point</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.358" spread="0.4083"/>
                    <measurement group_id="O2" value="0.214" spread="0.3582"/>
                    <measurement group_id="O3" value="1.258" spread="0.9249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Conjunctival Hyperemia Score</title>
        <description>Conjunctival hyperemia is the engorgement of the blood vessels (redness) of the clear membrane covering the white surface of the eye. Conjunctival hyperemia was evaluated 15 minutes post conjunctival allergen challenge (CAC) (8 hours post dose) on Day 1 for both eyes using a 9-point scale in half-unit increments where: 0=none to 4=Extremely severe. The score for each participant was the average of the score of both eyes.</description>
        <time_frame>Day 1</time_frame>
        <population>Modified Intent-to-treat (MITT) population included all randomized participants with ocular itching score data available for this time point</population>
        <group_list>
          <group group_id="O1">
            <title>AGN-229666 Dose A</title>
            <description>One drop of AGN-229666 Dose A into each eye on Day 1 and Day 15.</description>
          </group>
          <group group_id="O2">
            <title>AGN-229666 Dose B</title>
            <description>One drop of AGN-229666 Dose B into each eye on Day 1 and Day 15.</description>
          </group>
          <group group_id="O3">
            <title>Vehicle of AGN-229666</title>
            <description>One drop of vehicle of AGN-229666 into each eye on Day 1 and Day 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Conjunctival Hyperemia Score</title>
          <description>Conjunctival hyperemia is the engorgement of the blood vessels (redness) of the clear membrane covering the white surface of the eye. Conjunctival hyperemia was evaluated 15 minutes post conjunctival allergen challenge (CAC) (8 hours post dose) on Day 1 for both eyes using a 9-point scale in half-unit increments where: 0=none to 4=Extremely severe. The score for each participant was the average of the score of both eyes.</description>
          <population>Modified Intent-to-treat (MITT) population included all randomized participants with ocular itching score data available for this time point</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.387" spread="0.6118"/>
                    <measurement group_id="O2" value="1.345" spread="1.0531"/>
                    <measurement group_id="O3" value="1.633" spread="0.5972"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AGN-229666 Dose A</title>
          <description>One drop of AGN-229666 Dose A into each eye on Day 1 and Day 15.</description>
        </group>
        <group group_id="E2">
          <title>AGN-229666 Dose B</title>
          <description>One drop of AGN-229666 Dose B into each eye on Day 1 and Day 15.</description>
        </group>
        <group group_id="E3">
          <title>Vehicle of AGN-229666</title>
          <description>One drop of vehicle of AGN-229666 into each eye on Day 1 and Day 15.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head,</name_or_title>
      <organization>Allergan, Inc</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

